\begin{table}[htbp]
\centering
\caption{Group-Level ATT Estimates by Adoption Cohort}
\label{tab:group_att}
\begin{tabular}{lccccc}
\toprule
Cohort & ATT & SE & 95\% CI & States \\
\midrule
2013 & -0.0247** & (0.0102) & [-0.0447, -0.0047] & 3 \\
2014 & 0.0008 & (0.0199) & [-0.0382, 0.0398] & 3 \\
2015 & 0.0447** & (0.0212) & [0.0031, 0.0863] & 4 \\
2016 & 0.0224 & (0.0163) & [-0.0096, 0.0544] & 6 \\
2017 & -0.0099 & (0.0109) & [-0.0312, 0.0114] & 5 \\
2018 & 0.0339** & (0.0159) & [0.0027, 0.0650] & 9 \\
2019 & -0.0107 & (0.0104) & [-0.0310, 0.0096] & 12 \\
2020 & 0.0304*** & (0.0055) & [0.0195, 0.0413] & 2 \\
2021 & 0.0181 & (0.0143) & [-0.0099, 0.0462] & 2 \\
\midrule
Overall & 0.0101 & (0.0077) & [-0.0049, 0.0252] & 46 \\
\bottomrule
\end{tabular}
\begin{tablenotes}[flushleft]
\small
\item \textit{Notes:} Callaway and Sant'Anna (2021) group-level ATT estimates.
Cohort defined by the first full-exposure year of the must-access PDMP mandate.
Doubly-robust estimation with never-treated states as control.
Standard errors from multiplier bootstrap (1,000 iterations).
Post-treatment state-years per cohort: 2013: 33 (3 states $\times$ 11 years); 2014: 30 (3 $\times$ 10); 2015: 36 (4 $\times$ 9); 2016: 48 (6 $\times$ 8); 2017: 35 (5 $\times$ 7); 2018: 54 (9 $\times$ 6); 2019: 60 (12 $\times$ 5); 2020: 8 (2 $\times$ 4); 2021: 6 (2 $\times$ 3).
* $p < 0.1$, ** $p < 0.05$, *** $p < 0.01$.
\end{tablenotes}
\end{table}
